BiotechTube

Quizartinib + Salvage Chemotherapy

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

AML

Conditions

AML

Trial Timeline

May 1, 2014 → Sep 8, 2020

NCT ID
NCT02039726

About Quizartinib + Salvage Chemotherapy

Quizartinib + Salvage Chemotherapy is a phase 3 stage product being developed by Daiichi Sankyo for AML. The current trial status is completed. This product is registered under clinical trial identifier NCT02039726. Target conditions include AML.

What happened to similar drugs?

2 of 13 similar drugs in AML were approved

Approved (2) Terminated (1) Active (10)
✅Venetoclax + AzacitidineAbbVieApproved
✅Olutasidenib + CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP3A4, and OATP1B1 Probe SubstratesRigel PharmaceuticalsApproved
🔄gilteritinib + LoDAC (Low Dose Cytarabine) + Azacitidine + MEC (Mitoxantrone, Etoposide, Cytarabine) + FLAG-IDA (Granulocyte-Colony Stimulating Factor (G-CSF), Fludarabine, Cytarabine, Idarubicin)Astellas PharmaPhase 3
🔄gilteritinib + azacitidineAstellas PharmaPhase 3
🔄Gilteritinib + Cytarabine + Mitoxantrone + Etoposide + G-CSF + FludarabineAstellas PharmaPhase 3
🔄Venetoclax + Azacitidine + DecitabineAbbViePhase 3
🔄Venetoclax + Azacitidine + AzacitidineAbbViePhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02039726Phase 3Completed

Competing Products

20 competing products in AML

See all competitors
ProductCompanyStageHype Score
ZN-d5 ZN-c3 + ZN-c3Zentalis PharmaceuticalsPhase 1/2
14
AC220Daiichi SankyoPhase 1
29
QuizartinibDaiichi SankyoPhase 1
29
gilteritinibAstellas PharmaPre-clinical
26
gilteritinibAstellas PharmaPre-clinical
26
Gilteritinib + Venetoclax + AzacitidineAstellas PharmaPhase 1/2
36
Gilteritinib + PlaceboAstellas PharmaPhase 2
35
Venetoclax + GilteritinibAstellas PharmaPhase 1
29
GilteritinibAstellas PharmaPhase 1
29
Gilteritinib + Ivosidenib + EnasidenibAstellas PharmaPhase 1
36
gilteritinib + LoDAC (Low Dose Cytarabine) + Azacitidine + MEC (Mitoxantrone, Etoposide, Cytarabine) + FLAG-IDA (Granulocyte-Colony Stimulating Factor (G-CSF), Fludarabine, Cytarabine, Idarubicin)Astellas PharmaPhase 3
40
gilteritinib + atezolizumabAstellas PharmaPhase 1/2
32
Gilteritinib + Venetoclax + Azacitidine (AZA) + Local standard of care (SOC)Astellas PharmaPhase 2/3
45
gilteritinib + fludarabine + cytarabine + granulocyte colony-stimulating factor (G-CSF)Astellas PharmaPhase 1/2
24
ASP2215Astellas PharmaPre-clinical
26
ASP7517Astellas PharmaPhase 1/2
32
gilteritinib + azacitidineAstellas PharmaPhase 3
40
Gilteritinib + Cytarabine + Mitoxantrone + Etoposide + G-CSF + FludarabineAstellas PharmaPhase 3
44
decitabine Induction Chemotherapy + Induction ChemotherapyEisaiPhase 2
27
Decitabine + DecitabineEisaiPhase 2
27